The novel vaccine contained full tumor antigen hopeful to solve the problems of antigen delivery and host immunity enhancement

Herein, we report for the first time of the novel vaccine cell composed with allogenic mature dendritic cells (DCs) and inactive gastric cancer (GC) cells prepared by PEG mediated fusion. Combined with effecter of cytokine induced killing cells (CIKs), the immunotherapeutic and prophylactic potential of the fused vaccine cells (VCs) were evaluated in tumor-bearing, post-surgery and tumor free mice models. The migration and homing process of near infrared region quantum dots (NIR-QDs) labeled VCs were investigated by real-time animal imaging system. Results showed that the VCs and VC+CIKs could trigger the tumor-specific CTLs against GC cell, target the tumor tissue initiatively and enhance the prophylactic effects, suppress the tumor growth remarkably in vivo. The potential mechanism is also investigated. In conclusion, the novel vaccine cells can be used for targeted imaging and enhanced immunotherapeutic efficacy of GC, and hopeful to solve the double problems of antigen delivery and host immunity enhancement at the same time.